GM Canada Workers Approve C$1.1 Billion Investment Deal 
Jefferies Names AMEC Top China Semiconductor Equipment Pick 
Honda, Nissan Eye Shared Vehicle Software Platform by 2029 
SpaceX Mobile Network Could Cost Up to $130 Billion, Bernstein Says 
Aon Nears $17 Billion Deal to Buy USI Insurance From KKR 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
MediaTek Shares Jump 10% on Nvidia’s $3.5 Billion Investment 
Trump Secures Drug Pricing Deals With Nine Pharma Companies 
CIA-Linked Investor Helped Quantum Systems Expand in US 
Pinterest Stock Falls as CFO Julia Brau Donnelly Resigns 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Apple’s Phil Schiller Steps Back as Leadership Shake-Up Accelerates 
Faraday Future Delivers First Robots in Middle East, Plans September Launches 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Add as a preferred source on Google
CAMBRIDGE, Mass., March 21, 2018 -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) based on its Dolaflexin® and other proprietary platforms, today announced that it will host a conference call and webcast on Wednesday, March 28th, 2018, at 8:00 a.m. ET to report financial results for the fourth quarter and full year 2017 and provide business updates.
To access the call, please dial 866-363-0156 (domestic) or 706-902-3589 (international) and provide the Conference ID 2057979. A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at www.mersana.com.
About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop highly targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Mersana’s lead product candidate, XMT-1522, is in Phase 1 clinical trials in patients with advanced tumors expressing HER2, including breast cancer, non-small-cell-lung-cancer (NSCLC) and gastric cancer patients. The Company’s second product candidate, XMT-1536, is in Phase 1 clinical trials in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC and other cancers. In addition, multiple partners are using Mersana’s platform to advance their ADC pipelines.
Contacts:
Media Contact
Paul Kidwell, 617-680-1088
[email protected]
Or
Investor Contact
Stern Investor Relations, Inc.
Christina Tartaglia, 212-362-1200
[email protected]
